Last reviewed · How we verify
Azelastine , fluticasone
Azelastine is a selective H1-receptor antagonist and fluticasone is a corticosteroid that together reduce nasal inflammation and allergic responses.
Azelastine is a selective H1-receptor antagonist and fluticasone is a corticosteroid that together reduce nasal inflammation and allergic responses. Used for Allergic rhinitis (seasonal and perennial).
At a glance
| Generic name | Azelastine , fluticasone |
|---|---|
| Sponsor | University of Dundee |
| Drug class | Antihistamine and corticosteroid combination |
| Target | H1 receptor (azelastine); glucocorticoid receptor (fluticasone) |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Azelastine blocks histamine H1 receptors to reduce itching, sneezing, and allergic symptoms, while fluticasone propionate is a topical corticosteroid that suppresses inflammatory mediators and reduces nasal inflammation. This combination provides both rapid symptom relief and sustained anti-inflammatory effects for allergic rhinitis.
Approved indications
- Allergic rhinitis (seasonal and perennial)
Common side effects
- Headache
- Nasal irritation
- Bitter taste
- Epistaxis
Key clinical trials
- INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION (PHASE4)
- Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis (PHASE4)
- Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray
- Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis (PHASE4)
- Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER) (PHASE3)
- Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray (PHASE1)
- Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients
- Allergic Rhinitis Combination Pharmacotherapy Efficacy Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azelastine , fluticasone CI brief — competitive landscape report
- Azelastine , fluticasone updates RSS · CI watch RSS
- University of Dundee portfolio CI